Centene Stock Plummets 27%. What Sparked the Brutal Selloff. -- Barrons.com

Dow Jones
2025/07/02

By George Glover

Centene Corp. stock was plunging in premarket trading on Wednesday after the health insurance marketplace provider pulled its 2025 guidance, the latest bit of bad news for a sector that's been battered by ballooning medical costs.

Shares slumped 27% to $41.13 ahead of the opening bell. Futures tracking the S&P 500 were a touch higher.

Centene is a managed-care specialist focused on Medicaid and the Affordable Care Act insurance marketplaces. It said late Tuesday that preliminary data for 22 of its 29 marketplace states signaled that fewer customers than expected were enrolling in its plans, and those that have signed up were more likely to have health problems than previously forecast.

As a result, Centene expects a shortfall of $1.8 billion, which equates to a $2.75 a share hit to adjusted earnings. Analysts had been expecting full-year adjusted earnings of $7.28 a share, per a FactSet poll.

Centene withdrawing guidance is the latest development of a rough 2025 for health insurers, which are struggling to cope with surging healthcare costs. Shares in UnitedHealth Group tanked in May after the company pulled its own guidance, citing higher costs in its Medicare Advantage business. UnitedHealth also announced the departure of its CEO Andrew Witty due to personal reasons.

Shares in other health insurers were also falling Wednesday. Molina Healthcare sank 9% and Elevance Health dropped 3.7% in premarket trading.

Write to George Glover at george.glover@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

July 02, 2025 07:09 ET (11:09 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10